Receptor "hijacking" by malignant glioma cells: A tactic for tumor progression

Cancer Letters

Volumn 267, Issue 2, 2008, Pages 254-261

  Huang, Jian ^a,c   Chen, Keqiang ^a   Gong, Wanghua ^b   Zhou, Ye ^d   Le, Yingying ^e   Bian, Xiuwu ^c   Wang, Ji Ming ^a  

^a Center for Cancer Research   (United States)

^b SAIC FREDERICK INC   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Angiogenesis; Chemotaxis; Formyl peptide receptor; Glioma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMYLPEPTIDE RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PROTEIN BCL 2; STAT3 PROTEIN; TYROSINE; VASCULOTROPIN;

ANGIOGENESIS; BONE MARROW CELL; CANCER GROWTH; CELL ADHESION; CELL PROLIFERATION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; LEUKOCYTE ROLLING; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS);

EID: 47749135194     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.014     Document Type: Review

References (61)

1. Kesari S., and Stiles C.D. The bad seed: PDGF receptors link adult neural progenitors to glioma stem cells. Neuron 51 (2006) 151-153
2. Boring C.C., Squires T.S., Tong T., et al. Cancer statistics. CA Cancer J. Clin. 44 (1994) 7-26
3. Brada M., Sharpe G., Rajan B., et al. Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int. J. Radiat. Oncol. Biol. Phys. 43 (1999) 287-292
4. Winger M.J., Macdonald D.R., and Cairncross J.G. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J. Neurosurg. 71 (1989) 487-493
5. Shibamoto Y., Yamashita J., Takahashi M., et al. Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases. Radiother. Oncol. 18 (1990) 9-17
6. Reni M., Cozzarini C., Ferreri A.J., et al. A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme. Cancer Invest. 18 (2000) 510-515
7. Humphrey P.A., Wong A.J., Vogelstein B., et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. 48 (1988) 2231-2238
8. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50 (1990) 8017-8022
9. Huncharek M., and Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol. Res. 12 (2000) 107-112
10. Zawrocki A., and Biernat W. Epidermal growth factor receptor in glioblastoma. Folia Neuropathol. 43 (2005) 123-132
11. Haynik D.M., Roma A.A., and Prayson R.A. HER-2/neu expression in glioblastoma multiforme. Appl. Immunohistochem. Mol. Morphol. 15 (2007) 56-58
12. Angers-Loustau A., Hering R., Werbowetski T.E., et al. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol. Cancer Res. 2 (2004) 595-605
13. Lokker N.A., Sullivan C.M., Hollenbach S.J., et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62 (2002) 3729-3735
14. XW B., SX Y., JH C., et al. Preferential expression of the chemokine receptor CXCR4 by more highly malignant human gliomas and association with poor patient survival. Neurosurgery 61 (2007) 570-579
15. Zhou Y., Larsen P.H., Hao C., et al. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J. Biol. Chem. 277 (2002) 49481-49487
16. Yang S.X., Chen J.H., Jiang X.F., et al. Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 335 (2005) 523-528
17. Oh J.W., Drabik K., Kutsch O., et al. CXC chemokine receptor 4 expression and function in human astroglioma cells. J. Immunol. 166 (2001) 2695-2704
18. Zhou Y., Bian X., Le Y., et al. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J. Natl. Cancer Inst. 97 (2005) 823-835
19. Le Y., Hu J., Gong W., et al. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J. Neuroimmunol. 111 (2000) 102-108
20. Boulay F., Tardif M., Brouchon L., et al. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem. Biophys. Res. Commun. 168 (1990) 1103-1109
21. Boulay F., Tardif M., Brouchon L., et al. The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry 29 (1990) 11123-11133
22. Murphy P.M., Ozcelik T., Kenney R.T., et al. A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. J. Biol. Chem. 267 (1992) 7637-7643
23. Bao L., Gerard N.P., Eddy Jr. R.L., et al. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. Genomics 13 (1992) 437-440
24. Prossnitz E.R., and Ye R.D. The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol. Ther. 74 (1997) 73-102
25. Christophe T., Karlsson A., Dugave C., et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276 (2001) 21585-21593
26. Betten A., Bylund J., Christophe T., et al. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J. Clin. Invest. 108 (2001) 1221-1228
27. Gao J.L., Guillabert A., Hu J., et al. F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J. Immunol. 178 (2007) 1450-1456
28. Migeotte I., Riboldi E., Franssen J.D., et al. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J. Exp. Med. 201 (2005) 83-93
29. Durstin M., Gao J.L., Tiffany H.L., et al. Differential expression of members of the N-formylpeptide receptor gene cluster in human phagocytes. Biochem. Biophys. Res. Commun. 201 (1994) 174-179
30. Yang D., Chen Q., Gertz B., et al. Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. J. Leukoc. Biol. 72 (2002) 598-607
31. Yang D., Chen Q., Le Y., et al. Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. J. Immunol. 166 (2001) 4092-4098
32. Braun M.C., Wang J.M., Lahey E., et al. Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes. Blood 97 (2001) 3531-3536
33. Le Y., Murphy P.M., and Wang J.M. Formyl-peptide receptors revisited. Trends Immunol. 23 (2002) 541-548
34. Serhan C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?. Prostaglandins 53 (1997) 107-137
35. Sun R., Iribarren P., Zhang N., et al. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J. Immunol. 173 (2004) 428-436
36. Rabiet M.J., Huet E., and Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol. 35 (2005) 2486-2495
37. Xue M., Hsieh G., Raymond-Stintz M.A., et al. Activated N-formyl peptide receptor and high-affinity IgE receptor occupy common domains for signaling and internalization. Mol. Biol. Cell 18 (2007) 1410-1420
38. Haribabu B., Zhelev D.V., Pridgen B.C., et al. J. Biol. Chem. 274 (1999) 37087-37092
39. Wenzel-Seifert K., Arthur J.M., Liu H.Y., et al. Quantitative analysis of formyl peptide receptor coupling to g(i)alpha(1), g(i)alpha(2), and g(i)alpha(3). J. Biol. Chem. 274 (1999) 33259-33266
40. Pan Z.K., Chen L.Y., Cochrane C.G., et al. fMet-Leu-Phe stimulates proinflammatory cytokine gene expression in human peripheral blood monocytes: the role of phosphatidylinositol 3-kinase. J. Immunol. 164 (2000) 404-411
41. Gao J.L., Lee E.J., and Murphy P.M. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J. Exp. Med. 189 (1999) 657-662
42. Browning D.D., Pan Z.K., Prossnitz E.R., et al. Cell type- and developmental stage-specific activation of NF-kappaB by fMet-Leu-Phe in myeloid cells. J. Biol. Chem. 272 (1997) 7995-8001
43. Huang S., Chen L.Y., Zuraw B.L., et al. Chemoattractant-stimulated NF-kappaB activation is dependent on the low molecular weight GTPase RhoA. J. Biol. Chem. 276 (2001) 40977-40981
44. Niu G., Wright K.L., Huang M., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
45. Jung J.E., Lee H.G., Cho I.H., et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 19 (2005) 1296-1298
46. Wang M., Zhang W., Crisostomo P., et al. STAT3 mediates bone marrow mesenchymal stem cell VEGF production. J. Mol. Cell Cardiol. 42 (2007) 1009-1015
47. Zhang P., Wang Y., Hui Y., et al. Inhibition of VEGF expression by targeting HIF-1 alpha with small interference RNA in human RPE cells. Ophthalmologica 221 (2007) 411-417
48. Srinivasan D.M., Kapoor M., Kojima F., et al. Growth factor receptors: implications in tumor biology. Curr. Opin. Investig. Drugs 6 (2005) 1246-1249
49. Huang J., Hu J., Bian X., et al. Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells. Cancer Res. 67 (2007) 5906-5913
50. Dobashi Y., Takei N., Suzuki S., et al. Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod. Pathol. 17 (2004) 1497-1505
51. Layfield L.J., Willmore C., Tripp S., et al. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl. Immunohistochem. Mol. Morphol. 14 (2006) 91-96
52. Alvarez G., Perry A., Tan B.R., et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod. Pathol. 19 (2006) 942-949
53. Wang X., Zhang S., MacLennan G.T., et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin. Cancer Res. 13 (2007) 953-957
54. Wang X., Jones T.D., Zhang S., et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod. Pathol. 20 (2007) 175-182
55. Zhang X., and Chang A. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J. Med. Genet. 44 (2007) 166-172
56. Hoadley K.A., Weigman V.J., Fan C., et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genom. 8 (2007) 258
57. Meyers M.B., Merluzzi V.J., Spengler B.A., et al. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc. Natl. Acad. Sci. USA 83 (1986) 5521-5525
58. Le Y., Gong W., Li B., et al. by the synthetic hexapeptide WKYMVm for human phagocyte activation. J. Immunol. 163 (1999) 6777-6784
59. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
60. Wang J.M., Deng X., Gong W., et al. Chemokines and their role in tumor growth and metastasis. J. Immunol. Methods 220 (1998) 1-17
61. Wang J.M., Chertov O., Proost P., et al. Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NFkappaB activation. Int. J. Cancer 75 (1998) 900-907